Fintel, a financial intelligence website, reports that on May 26, 2023, Citigroup maintained coverage of 23andMe Holding Co (NASDAQ: ME), a leading consumer genetics and research company, with a Neutral recommendation. As of May 11, 2023, the average one-year price target for 23andMe Holding Co is $5.80, with an increase of 178.91% from its latest reported closing price of $2.08.
23andMe, Inc., headquartered in Sunnyvale, CA, has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers participating. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases.
There are 303 funds or institutions reporting positions in 23andMe Holding Co, indicating an increase of 13 owners or 4.48% in the last quarter. The put/call ratio of ME is 0.12, indicating a bullish outlook.
Several significant shareholders maintain their positions in 23andMe. NewView Capital Partners I holds 19,456K shares representing 4.25% ownership of the company. Euclidean Capital holds 10,243K shares representing 2.24% ownership of the company. VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 8,502K shares representing 1.86% ownership of the company. NAESX – Vanguard Small-Cap Index Fund Investor Shares holds 7,159K shares representing 1.57% ownership of the company. Alphabet holds 6,737K shares representing 1.47% ownership of the company.
This information was sourced from Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
